Neurology Program(s)

About Mercury Bio

Mercury Bio is a private, pre-clinical stage biotech company pioneering a novel approach to treating diseases driven by intracellular pathology. The company's proprietary MB-TIP™ platform combines engineered nanobodies (yEV™) and AI-informed design to deliver proteins, nanobodies, RNA, and small molecules across biological barriers and into cells, a significant challenge for existing biologics. With an initial focus on high-unmet-need neurodegenerative diseases, Mercury Bio aims to move beyond symptom management to potentially alter disease progression by targeting pathogenic proteins inside neurons. The company is advancing a pipeline across neurology, oncology, regenerative medicine, metabolic, and viral diseases, with pre-clinical validation from research partners like Vanderbilt University.

About Afecta Pharmaceuticals

Afecta Pharmaceuticals is a private, pre-revenue biotech leveraging a proprietary technology platform to discover and develop precision small molecule drugs. Its pipeline spans neurology, ophthalmology, oncology, and dermatology, with programs in early clinical stages. Founded by physician-scientists and led by industry veterans, the company employs a collaborative business model, having previously licensed its first discovered drugs to Supernus Pharmaceuticals and listing several major pharma companies as industry partners.

Therapeutic Areas

Other Neurodegenerative diseases (e.g., Parkinson's, Alzheimer's) Drugs